目的 系统评价维泊妥珠单抗在真实世界对复发/难治弥漫大B细胞淋巴瘤的疗效和安全性.方法 检索PubMed、Embase、Web of Science核心合集数据库、中国知网和万方数据知识服务平台建库至2024年2月,维泊妥珠单抗治疗复发/难治弥漫大B细胞淋巴瘤研究文献,使用非随机对照试验方法学评价指标量表对纳入分析文献质量评估,提取文献数据进行meta分析.结果 本研究纳入11项真实世界研究,总病例数551例.经meta分析合并后总缓解率为51％(95％CI:44％～58％,P=0.003)、完全缓解率为15％(95％CI:12％～19％,P=0.051),平均总生存期为7.61个月(95％CI:5.67～9.55,P＜0.000).安全性方面部分不良事件发生率偏高.亚组分析方面治疗线数较少的患者总生存期获益更多.结论 维泊妥珠单抗治疗复发/难治弥漫大B细胞淋巴瘤真实世界中的有效性和安全性良好,但目前真实世界研究较少且样本量偏小,有待更多研究开展.
Meta-analysis of real-world efficacy and safety of polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma
Objective To systematically review the real-world efficacy and safety of polatuzumab vedotin in the treatment of recurrent/refractory diffuse large B-cell lymphoma.Methods From inception to February,2024,PubMed,Embase,Web of Science Core Collection Database,CNKI,and Wanfang Data were retrieved to collect the treatment of diffuse large B-cell lymphoma with polatuzumab vedotin.The methodological index for non-randomized studies scale was used to evaluate the quality of the literature,and extract literature data for meta-analysis.Results This study included 11 real-world studies involing 551 patients.Meta-analysis results showed that the overall response rate was 51％(95％CI:44％-58％,P=0.003),complete remission rate was 15％(95％CI:12％-19％,P=0.051),mean overall survival was 7.61 months(95％CI:5.67-9.55,P＜0.000).The incidence of some adverse events in terms of safety is relatively high.In the subgroup analysis,patients with fewer prior lines of treatment benefit more in terms of overall survival.Conclusion Polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma has good curative effect and safety,but the sample size of the included studies is too small,so it is necessary to conduct real-world studies in the future.
Polatuzumab vedotinRelapsed/refractory diffuse large B-cell lymphomaReal word studiesEfficacySafetymeta-analysis
NETL
NSTL
万方数据
